Last reviewed · How we verify

NCT03336008: HK_SCA_Reg

Hong Kong Spinocerebellar Ataxias Registry

Recruiting now Last updated 27 August 2024
What this trial tests

trial testing no intervention in Spinocerebellar Ataxia in 300 participants. Currently enrolling.

Timeline
7 December 2012
Primary endpoint
31 December 2034
31 December 2034

Quick facts

Lead sponsorChinese University of Hong Kong
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment300
Start date7 December 2012
Primary completion31 December 2034
Estimated completion31 December 2034
Sites1 location across Hong Kong

Drugs / interventions tested

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

Adults 18 to 90, any sex, with Spinocerebellar Ataxia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Spinocerebellar ataxias (SCA) 1, 2, 3 and 6 are the most common, autosomal dominantly inherited cerebellar degenerations. And in the Chinese population, the most common SCA is SCA3 and the frequency of SCA 3 among SCA patients is 72.5%, followed by SCA 2 that the frequency is 12% among SCA patients. For SCA 1, the frequency among SCA patients is 7%. Even SCAs are rare diseases, a significant amount of Chinese in Hong Kong still suffer from this disorders. SCA Association in Hong Kong has 88 members who are suffering from spinocerebellar degeneration, many of them have a genetic confirmation. As there are few treatments for SCAs; therefore, understanding SCAs clinical manifestation and disease mechanisms are the first step towards development of effective treatment. The objective of this study is to develop the first SCA registry in Hong Kong with bio-repository bank for clinical and genetic information as well as serum and fibroblasts.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of no intervention

Trials testing the same drug.

Other recruiting trials for Spinocerebellar Ataxia

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03336008.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing